| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c8881c9fd379ae927607ba3bba049b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce147edebda4401efaec7e5b9b49e95a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd29a50767c502591662f84f9422269d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C259-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-68 |
| filingDate |
2010-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97f7172f673d9de7f60dd1c80e266bb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81cc70459a95b51f8427b9db455f915f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42d8cee6523507171e43964b19d8c61d |
| publicationDate |
2012-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012203014-A1 |
| titleOfInvention |
Derivatives of n-hydroxybenzamide for treating hiv infections |
| abstract |
Herein disclosed is a method for treating patients affected by HIV comprising administering N-hydroxy-benzamide-based histone deacetylase inhibitors, such as: diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxymethyl)-naphtalen-2-yl-methyl]-ammonium chloride; 4-(2-(S)-benzoylamino-3-naphtalen-2-yl-propionylamino)-N-hydroxy-benzamide; and/or benzo[1,3]dioxole-5-carboxylic acid [1(S)-(4-hydroxycarbamoyl-phenylcarbamoyl)-2-naphtalen-2-yl-ethyl]-amide. Such histone deacetylase inhibitors are administered in a dosage ranging from 50 to 200 mg/day, preferably from 100 to 200 mg/day, so as to obtain a blood concentration between 125 and 250 nM. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018075564-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11149082-B2 |
| priorityDate |
2009-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |